The company has not released the underlying data publicly, citing the confidentiality of the application, but its public summary indicates the geometric mean ratios for area under the curve and maximum concentration fell within the FDA's accepted 80125 percent equivalence window
populationtaking these medications, the industry is booming
Patients using tirzepatide averaged about 20% weight loss over 72 weeks in similar studies
Their subsequent investigation revealed that Nrf2 levels decreased in DKD mice, but fenofibrate therapy could upregulate Nrf2, preventing ferroptosis [149]
Plus, these surprise drugs constitute perhaps the most exciting treatment possibility ever seen in ME/CFS, FM, long COVID, and related diseases
Srensen G, Caine SB, Thomsen M